To improve national security at the National Institutes of Health, to address national security issues in the licensure of biological products, to address national security considerations in research at the Department of Health and Human Services, and for other purposes.

IN THE SENATE OF THE UNITED STATES

MAY 20, 2021

Mr. RUBIO introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To improve national security at the National Institutes of Health, to address national security issues in the licensure of biological products, to address national security considerations in research at the Department of Health and Human Services, and for other purposes.

1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
3 SECTION 1. SHORT TITLE.
4 This Act may be cited as the “Genomics Data Secu-
5 rity Act”.

S. 1744
SEC. 2. MODERNIZING THE NATIONAL INSTITUTES OF HEALTH’S APPROACH TO NATIONAL SECURITY.

Section 402(m)(2) of the Public Health Service Act (42 U.S.C. 282(m)(2)) is amended—

(1) in subparagraph (E), by striking ‘‘; and’’ and inserting a semicolon;

(2) by redesignating subparagraph (F) as subparagraph (G); and

(3) by inserting after subparagraph (E) the following:

“(F) address national security issues, including ways in which the National Institutes of Health can engage with other Federal agencies to modernize the national security strategy of the National Institutes of Health; and”.

SEC. 3. UTILIZATION OF GENOMIC SEQUENCING SERVICES BY THE NATIONAL INSTITUTES OF HEALTH.

Notwithstanding any other provision of law, no amounts made available to the National Institutes of Health may be used with respect to activities carried out by any company or its subcontractors or subsidiaries—

(1) over which control is exercised or exercisable by the Government of the People’s Republic of China, a national of the People’s Republic of

S 1744 IS
China, or an entity organized under the laws of the
People’s Republic of China; or

(2) in which the Government of the People’s
Republic of China has a substantial interest.

SEC. 4. NATIONAL SECURITY CONSIDERATIONS THROUGH
LICENSURE.

Section 353 of the Public Health Service Act (42
U.S.C. 263a) is amended—

(1) by redesignating subsection (q) as sub-
section (r); and

(2) by inserting after subsection (p) the fol-
lowing:

“(q) TIES TO THE PEOPLE’S REPUBLIC OF CHINA.—

“(1) IN GENERAL.—Each certificate issued by
the Secretary under this section shall state wheth-
er—

“(A) the laboratory;

“(B) the company that owns or manages
the laboratory; or

“(C) any subcontractors or subsidiaries of
such a laboratory or company,

is an entity described in paragraph (2).

“(2) ENTITY DESCRIBED.—An entity described
in this paragraph is an entity—
“(A)(i) that is engaged in the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, people of the United States; or

“(ii) that handles or has access to any data related to people of the United States that is derived from any activity described in clause (i); and

“(B)(i) over which control is exercised or exercisable by the Government of the People’s Republic of China, a national of the People’s Republic of China, or an entity organized under the laws of the People’s Republic of China; or

“(ii) in which the Government of the People’s Republic of China has a substantial interest.”.

SEC. 5. NIH GRANTEE TIES TO FOREIGN GOVERNMENTS.

Title IV of the Public Health Service Act is amended by inserting after section 403C (42 U.S.C. 283a–2) the following:
SEC. 403C–1. ANNUAL REPORTING REGARDING GRANTEE TIES TO FOREIGN GOVERNMENTS.

“(a) IN GENERAL.—On an annual basis, the Director of NIH shall submit to the Committee on Health, Education, Labor, and Pensions, the Committee on Foreign Relations, and the Select Committee on Intelligence of the Senate, and to the Committee on Energy and Commerce, the Committee on Foreign Affairs, and the Permanent Select Committee on Intelligence of the House of Representatives, a report on any ties to foreign governments that researchers funded by grants from the National Institutes of Health have and that are not properly disclosed, vetted, and approved by the National Institutes of Health, including the status of any ongoing National Institutes of Health compliance reviews related to such ties and all administrative actions taken to address such concerns.

“(b) REQUIREMENT.—The Committees receiving the reports under subsection (a) shall keep confidential, and shall not release, any provision of such a report that is related to an ongoing National Institutes of Health compliance review.”.

SEC. 6. NATIONAL SECURITY CONSIDERATIONS IN RESEARCH.

(a) ESTABLISHMENT OF WORKING GROUP.—Not later than 120 days after the date of enactment of this Act, the Secretary of Health and Human Services (re-
ferred to in this section as the “Secretary”) shall establish
a working group (in this Act referred to as the “Working
Group”) in the Department of Health and Human Serv-
ices to make recommended updates to the National Insti-
tute of Health’s Genomic Data Sharing Policy and to that
end, develop and disseminate best practices on data shar-
ing for use by entities engaged in biomedical research and
international collaboration to enable both academic, pub-
lie, and private institutions to—

(1) protect intellectual property;

(2) weigh the national security risks of poten-
tial partnerships where sensitive health information
(for purposes of this Act, as defined by the Health
IT Policy Committee), of the people of the United
States is exchanged; and

(3) protect the sensitive health information of
the people of the United States.

(b) MEMBERSHIP.—

(1) COMPOSITION.—The Secretary shall, after
consultation with the Director of the National
Science Foundation and the Attorney General, ap-
point to the Working Group—

(A) individuals with knowledge and exper-
tise in data privacy or security, data-sharing,
national security, or the uses of genomic tech-
ology and information in clinical or non-clinical research;

(B) representatives of national associations representing biomedical research institutions and academic societies;

(C) representatives of at least 2 major genomics research organizations from the private sector; and

(D) representatives of any other entities the Secretary determines appropriate and necessary to develop the best practices described in subsection (a).

(2) REPRESENTATION.—In addition to the members described in paragraph (1), the Working Group shall include not less than one representative of each of the following:

(A) The National Institutes of Health.

(B) The Bureau of Industry and Security of the Department of Commerce.

(C) The National Academies of Science, Engineering, and Mathematics.

(D) The Department of State.

(E) The Department of Justice.

(F) The Federal Health IT Coordinating Council.
(G) The Office of the National Coordinator

for Health Information Technology.

(H) The Defense Advanced Research

Projects Agency.

(I) The Department of Energy.

(3) DATE.—The appointments of the members

of the Working Group shall be made not later than

90 days after the date of enactment of this Act.

(e) DUTIES OF WORKING GROUP.—

(1) STUDY.—The Working Group shall study—

(A) the transfer of data between private,

public, and academic institutions that partake

in science and technology research and their re-

search partners, with a focus on entities of the

People’s Republic of China and other foreign

entities of concern, including a review of what

circumstances would constitute a transfer of

data;

(B) best practices regarding data protec-
tion to help private, public, and academic insti-
tutions that partake in biomedical research de-
cide how to weigh and factor national security

into their partnership decisions and, through

research collaborations, what steps the institu-
tions can take to safeguard data, particularly
 genomic data;

(C) recommendations regarding areas
where Federal agencies can coordinate to in-
crease education to such private and academic
research institutions that partake in science
and technology research to ensure the institu-
tions can better protect themselves from eco-
nomic threats with a strengthened under-
standing of intellectual property rights, re-
search ethics, and the risk of intellectual prop-
erty theft, as well as education on how to recog-
nize and report such threats; and

(D) other risks and best practices related
to information and data sharing, as identified
by the Working Group, including any gaps in
current practice that could be addressed by con-
gressional action.

(2) REPORT.—

(A) IN GENERAL.—Not later than 1 year
after the date of enactment of this Act, the
Working Group shall submit a report that con-
tains a detailed statement of the findings and
conclusions of the Working Group, together
with recommendations to update the National
Institute of Health’s Genomic Data Sharing Policy and subsequent nonbinding guidance regarding risks and safeguards for data sharing with foreign entities for research institutions in the field, to—

(i) the Secretary of Health and Human Services;

(ii) the President;

(iii) the Committee on Health, Education, Labor, and Pensions, the Committee on Foreign Relations, and the Select Committee on Intelligence of the Senate; and

(iv) the Committee on Energy and Commerce, the Committee on Foreign Affairs, and the Permanent Select Committee on Intelligence of the House of Representatives.

(B) GUIDANCE.—The guidance provided under subparagraph (A) shall include non-binding guidance for entities that utilize genomic technologies, such as whole genomic sequencing, for use in research or other types of sensitive health information, as defined by the Secretary.
(3) REQUIREMENTS.—In carrying out the duties of this subsection, the Working Group shall consider all existing Federal guidance and grant requirements (as of the date of consideration), particularly with regard to foreign influences and research integrity, and ensure that all recommended updates to the Genomic Data Sharing Policy and subsequent best practices put forward by the working group not duplicate or conflict with existing guidance, as of the date of publication.

(d) POWERS OF WORKING GROUP.—

(1) HEARINGS.—The Working Group may hold such hearings, sit and act at such times and places, take such testimony, and receive such evidence as the Working Group considers advisable to carry out this Act.

(2) INFORMATION FROM FEDERAL AGENCIES.—

(A) IN GENERAL.—The Working Group may secure directly from a Federal department or agency such information as the Working Group considers necessary to carry out this Act.

(B) FURNISHING INFORMATION.—On request of a majority of the members of the Working Group, the head of the department or
agency shall furnish the information to the
Working Group.

(3) POSTAL SERVICES.—The Working Group
may use the United States mails in the same man-
ner and under the same conditions as other depart-
ments and agencies of the Federal Government.

(e) TERMINATION OF WORKING GROUP.—The Work-
ing Group shall terminate 90 days after the date on which
the Working Group submits the report required under
subsection (e)(2).